Calidi Biotherapeutics Achieves Successful Offering
Calidi Biotherapeutics, Inc. (NYSE: CLDI), a company renowned for its pioneering efforts in clinical-stage biotechnology, has captured attention after successfully closing a significant underwritten public offering. This financing effort has garnered gross proceeds of $6.9 million, paving the way for further advancements in their cutting-edge therapeutic applications.
Details of the Public Offering
The recent offering comprised a sale of 1,922,764 common stock units. Each unit consists of one share of common stock coupled with a Series I warrant allowing the purchase of an additional share of common stock. Additionally, 1,528,000 pre-funded warrant units were sold. Each pre-funded unit includes a pre-funded warrant and a Series I warrant.
Pricing and Warrant Features
Common stock units were priced at $2.00 each, while pre-funded units were offered at $1.999. Notably, the Series I warrants feature a fixed exercise price of $2.00 per share, making them accessible upon issuance and valid for five years from that date.
Role of Underwriters in the Offering
Ladenburg Thalmann & Co. Inc. served as the sole book-running manager for the offering, with Laidlaw & Company (U.K.) Ltd. participating as a co-manager. Their expertise in the financial market contributes significantly to the operational success of such public offerings.
Regulatory Approvals and Compliance
The securities sold were issued under a registration statement that received SEC approval, ensuring compliance with the necessary regulations. This acknowledgment from the SEC indicates a level of trust and validation of Calidi's strategies in engaging with the market.
About Calidi Biotherapeutics
Calidi Biotherapeutics is on a mission to redefine cancer treatment paradigms. At the core of their research is the Redtail platform, which utilizes an engineered enveloped oncolytic virus. This technology aims to enhance systemic delivery to neglected sites of disease and promote targeted therapeutic actions.
Focus on Innovative Cancer Treatments
The lead candidate from the Redtail platform is under rigorous IND-enabling studies and targets various cancers, including non-small cell lung cancer and ovarian cancer – conditions with significant unmet needs. In addition, Calidi is also developing localized virotherapies, which are currently in clinical stages, designed for injection into tumor sites.
Future Prospects for Calidi
Looking ahead, Calidi Biotherapeutics aims to expand its innovative therapeutic footprint, potentially revolutionizing how specific cancers are treated. With substantial funding secured, the company is well-positioned to further its clinical trials and explore new avenues in oncology therapies.
Investor Relations Contact
For more insights into Calidi's business cycles and operational strategies, interested parties can reach out to the company's dedicated investor relations. Dave Gentry, CEO of RedChip Companies, Inc., is available for inquiries at 1-407-644-4256 or via email.
Frequently Asked Questions
What was the total amount raised in Calidi's recent public offering?
Calidi Biotherapeutics raised a total of $6.9 million through its recent public offering.
Who managed the underwritten public offering for Calidi?
Ladenburg Thalmann & Co. Inc. acted as the sole book-running manager, with Laidlaw & Company (U.K.) Ltd. serving as a co-manager.
What is the main focus of Calidi Biotherapeutics' research?
The company specializes in developing targeted therapies and innovative cancer treatments, utilizing their proprietary Redtail platform.
What types of warrants were issued in the offering?
Calidi issued Series I warrants alongside each common stock unit and pre-funded unit, allowing purchases of additional shares at a set price.
How is Calidi positioning itself for future growth?
With the funds from the offering, Calidi aims to enhance their clinical trials and expand their pipeline of innovative cancer therapies.
